A chiral liquid chromatography tandem mass spectrometry (LC -MS-MS) method was developed and validated for quantifying methylphenidate and its major metabolite ritalinic acid in blood from forensic cases. Blood samples were prepared in a fully automated system by protein precipitation followed by solid-phase extraction. The LC-MS-MS method was linear in the range of 0.5 to 500 ng/g for the enantiomers of both analytes. For concentrations above the limit of quantification, coefficients of variation were 15% or less, and the accuracy was 89 to 94%. For 12 postmortem samples in which methylphenidate was not determined to be related to the cause of death, the femoral blood concentration of d-methylphenidate ranged from 5 to 58 ng/g, and from undetected to 48 ng/g for l-methylphenidate (median d/l-ratio 5.9). Ritalinic acid was present at concentrations 10-20 times higher with roughly equal amounts of the d-and l-forms. In blood from 10 living subjects that were not suspected of being intoxicated by methylphenidate, the concentration ranges and patterns were similar to those of the postmortem cases. Thus, methylphenidate does not appear to undergo significant postmortem redistribution.
Introduction
Methylphenidate (MPH) is used for the treatment of attentiondeficit hyperactivity disorder (ADHD) and narcolepsy, but has also been prescribed for the off-label treatment of other disorders such as lethargy. The drug is a CNS stimulant and inhibits the reuptake of dopamine in the synapses (1) . The use of MPH has increased considerably in recent years. Abuse of the drug has also escalated, which makes it of interest in a forensic context (2) . The MPH molecule contains a piperidine ring, benzene ring and methylester group (Figure 1 ). MPH contains two stereogenic centers, resulting in a total of four possible stereoisomers: dextro and levo enantiomers of erythro-and threo-MPH (3). Most modern pharmaceutical formulations of the drug contain the two threo enantiomers as a racemic mixture, because only the threo enantiomers result in the desired pharmacological effect, whereas the erythro enantiomers exert only hypertensive and toxic effects (4) . Newer studies have indicated that of the two threo enantiomers, only the d-form is responsible for the desired therapeutic effects (5 -7) . Below threo-MPH or -ritalinic acid (RA) will be referred to as simply MPH or RA, respectively.
MPH has considerable first-pass metabolism consisting of hydrolysis of the ester group, resulting in the de-esterified, pharmacologically inactive metabolite RA. The hydrolysis is catalyzed by carboxylesterase 1 (CES1), which in humans is primarily expressed in the liver and adipose tissue. The enzyme exhibits enantioselectivity, preferring l-MPH over d-MPH (8) . Similar to other ester-containing drugs, MPH also exhibits spontaneous nonenantioselective hydrolysis in solution. Furthermore, there seems to be an enzyme-mediated hydrolysis in human plasma. The hydrolysis in human plasma is characterized by the opposite enantioselectivity compared to CES1-mediated hydrolysis in the liver because d-MPH is preferred over l-MPH (9) .
Individual variations in the rate of the metabolism of MPH with possible clinical significance have been reported. This includes reports of individuals with significantly decreased metabolism of this drug, so-called poor metabolizers (10, 11) . Such decreased metabolism or lack in the ability to metabolize MPH can be genetically determined. This is supported by findings of single-nucleotide substitutions in the coding region of the gene encoding CES1 in individuals with a poor metabolizer phenotype (12) . One of these variants was associated with a stereospecific change in the metabolism of MPH and manifested an extraordinarily high serum concentration of the l-form of the drug (12) . This finding opens possibilities for the identification of poor metabolizers by estimation of the d/l-ratio of MPH in serum.
Several methods have been developed for the analysis of MPH and RA in various biological matrices. Liquid chromatography-mass spectrometric (LC -MS) methods have been developed for the analysis of MPH and/or RA in plasma (10, 13 -25) , urine (23, 26, 27) , oral fluid (23, 24) , sweat (23) or hair (28) . In a recent study, MPH and RA were analyzed in human whole blood (non-chiral), which is an important matrix in forensic investigations (24) . Several of these studies chirally analyzed either MPH or RA, but none chirally analyzed both substances in the same method. A simultaneous detection of all four analytes, i.e., the d-and l-forms of both MPH and RA, could be advantageous because it would provide more detailed information about the ability of a subject to metabolize MPH.
The physicochemical properties of the two substances are very different; RA contains a carboxylic acid group, which, together with the piperidine ring, makes it an ampholytic substance, whereas MPH lacks the acid group and is a basic substance. These physicochemical differences lead to difficulties in extracting the two substances from biological matrices and chromatographically separating them using the same method, although Doerge et al. demonstrated a method for the simultaneous extraction of the two substances from plasma using solid-phase extraction (SPE) (16) .
In forensic and clinical investigations of drugs existing in racemic mixtures of a biologically active and an inactive form such as d/l-MPH, the ability to specifically determine the active compound is crucial. This, combined with the potential for identifying subclasses of poor metabolizers by determining a change in the d/l-ratio, underlines the relevance and prospects of an assay allowing enantiomer-specific determination of methylphenidate and its main metabolite.
This study developed such a method, allowing the simultaneous determination of MPH and RA in human whole blood based on liquid chromatography coupled with mass spectroscopy.
Experimental
Chemicals, reagents, and reference compounds The rac-threo-MPH and -RA were from Cerilliant (Round Rock, TX) and Novartis (Basel, Switzerland), respectively; d-threo-MPH and the deuterated internal standards rac-threo-MPH-d10 and rac-threo-RA-d10 were from Toronto Research Chemicals (Toronto, Canada). Stock solutions of standards (1,000 mg/L) and the internal standards (100 mg/L) were prepared in methanol and stored at -208C. Separately diluted internal standard stock solutions (0.5 mg/L) for MPH and RA were prepared in water, aliquoted into 1.5-mL amber vials, and stored at -208C until use. A 5-mg/L diluted stock solution of the four analytes was prepared in water, aliquoted into amber vials and stored at -208C until use.
Methanol, isopropanol and acetonitrile were LC-MS grade (Fisher Scientific UK, Leicestershire, UK). Formic acid ( 98%) and analytical-grade ammonium formate were obtained from Fluka (Buchs, Switzerland). Analytic-grade acetic acid was obtained from Merck (Darmstadt, Germany). Purified water was obtained from a Millipore Synergy UV water purification system (Millipore A/S, Copenhagen, Denmark).
Blank human whole blood (BB) was purchased from the blood bank at Copenhagen University Hospital (Copenhagen, Denmark), preserved by adding 1% sodium fluoride and stored at -208C. The addition of sodium fluoride and subsequent freezing of the blood induces hemolysis of the blood cells. BB was used for spiked calibrators, negative controls, blank with internal standards, quality control (QC) samples, and validation studies.
Preparation of internal standards, calibrators, and QC samples A combined internal standard working solution (IS) with 7.5 mg/L MPH-d10 and 10 mg/L RA-d10 was prepared daily by dilution of the two 0.5-mg/L internal standard stock solutions in water. Solutions for spiking calibrator samples were prepared at five concentrations (0.005, 0.01, 0.1, 1 and 5 mg/L). The 5-mg/L concentration was used immediately. The other four concentrations were prepared in-run by the robotic system from the diluted stock solution using serial dilution in water. The ability of the robotic system to accurately pipet the relevant volumes of liquid has been verified and is described elsewhere (29) .
QC samples were prepared at two concentrations (1 and 100 ng/g), aliquoted into 1-mL Nunc Cryotubes and stored at -208C. Weighted amounts of BB were spiked with mixed working solutions of MPH and RA prepared from another lot of stock solutions (1,000 mg/L in methanol) diluted in water. QC samples were analyzed in each run and registered in a QC chart.
Sample preparation
The sample preparation was automated on a Freedom EVO 150 robotic system (Tecan, Ma¨nnedorf, Switzerland) equipped with a liquid handling arm, robotic manipulator arm, Te-VacS vacuum station, Te-Shake microplate shaker station, UltraVap sample concentrator (Porvair Sciences, Leatherhead, UK), XP203S precision balance (Mettler-Toledo, Greifensee, Switzerland) and X-seal automatic thermal sealer (Cedrex, Karlslunde, Denmark). The system was programmed and controlled using Tecan Evoware 2.3 SP3 software. A more detailed description of the robotic system setup is provided by Anderson et al. (29) .
Two hundred microliters of blood was transferred to a 96-well microtiter plate, and the accurate mass was measured by the precision balance. Twenty microliters of IS and, for calibrators and other spiked samples, 20 mL of standard working solution were then added. Water was added to achieve an equal volume of 240 mL in each well. After two minutes of shaking, 600 mL of 15% methanol in acetonitrile was added, followed by another two minutes of shaking. The samples were centrifuged at 2,000 g for 5 min using an Eppendorf 5804R centrifuge (Eppendorf, Hamburg, Germany), and 600 mL of the supernatant was evaporated to dryness by nitrogen gas at 358C using a gas pressure of 6 psi for 50 min. The samples were reconstituted in 500 mL of 2% acetic acid in water.
A 96-well Strata-X SPE plate with a bed mass of 30 mg and well volume of 2 mL (Phenomenex, Torrance, CA) was conditioned with 900 mL methanol, followed by equilibration with 900 mL of 2% acetic acid in water. Vacuum suction was used to remove the fluid from the plate. The samples were loaded on the plate, left for 60 s, and washed with 900 mL of 5% methanol and 2% acetic acid in water. The samples were eluted from the plate using 500 mL of 50% methanol and 2% acetic acid in water. The eluates were evaporated to dryness using the previously mentioned conditions for 80 min. The final step was reconstitution in 50 mL of mobile phase.
Samples found to contain a concentration of RA higher than 500 ng/g were diluted by adding two volumes of water and re-analyzed. 
LC -MS-MS procedure
Chromatographic separation was performed using an Agilent 1100 series HPLC system from Agilent Technologies (Waldbronn, Germany) consisting of a binary pump, degasser, thermostated column compartment and 1200 series autosampler. A Chiral-AGP column (100 Â 4.0 mm, i.d. 5 mm) and matching guard column (10 Â 4 mm, i.d. 5 mm) were used (both from Sigma-Aldrich, St. Louis, MO). An isocratic method was applied with mobile phase consisting of 10 mM ammonium formate and 0.4% isopropanol, adjusted to pH 5.4 with formic acid. The system was conditioned with mobile phase for 60 min before the first injection. The flow rate was 0.6 mL/min, the column temperature was set to 258C, and 20 mL was injected into the HPLC system.
A Quattromicro triple quadrupole tandem mass spectrometer (Waters, Manchester, UK) was coupled to the HPLC system. Data were acquired in positive electrospray ionization mode using Masslynx 4.1 software (Waters). MS conditions were optimized by infusion of a standard solution through a T-piece using the autotune function in the software. Multiple reaction monitoring (MRM) was used for data collection. The applied conditions and transitions are provided in Table I . Other MS parameters were a capillary voltage of 1 kV, source temperature of 1208C, desolvation temperature of 3508C, cone gas flow of 30 L/h and desolvation gas flow of 800 L/h. Argon was used as collision gas.
Method validation
The method was validated for selectivity, linearity, accuracy, precision, recovery, carryover and stability using the guidelines of Peters et al. (30) . Selectivity was assessed by injecting three standard mixtures: a mixture of 15 common drugs of abuse and two of their metabolites, a mixture of 12 common benzodiazepines and five of their metabolites and a mixture of 100 therapeutic drugs and drugs of abuse. The MRM tracks of the analytes were then monitored for potential interfering peaks. Cross interference between the four analytes and their internal standards was also examined by injecting them separately.
Ion suppression/enhancement was investigated by postcolumn infusion of a mixed solution of the four analytes and their corresponding internal standards into a T-piece, mixing it with the column effluent. The possible influence of the matrix was then examined by injecting 11 extracts of whole blood (five from postmortem cases, five from living donors and one BB) that tested negative for the analytes. Phospholipids were monitored by two surviving ions, 104 . 104 and 184 . 184, using cone voltages of 90 and 70, respectively, and a collision energy of 7 eV, as suggested by Ismaiel and coworkers (31) .
Linearity was established by analyzing spiked BB at six concentrations (0.2, 0.5, 1, 10, 100 and 500 ng/g) in six replicates. Calibration graphs were derived by plotting the ratio of the areas of the analyte and IS versus the spiked concentration of the analytes using Targetlynx software (Waters). Both linear and polynomial calibration models were considered, and deviation from linearity was tested by comparing the second-order coefficient against 0 using the Student's t-test (32) . Weighting factors were assessed by comparing the variances of the lowest and highest concentrations using the F-test.
Accuracy and precision were determined by analyzing two replicates at four concentrations (0.5, 10, 100 and 500 ng/g) in five different runs. Accuracy was then calculated as the ratio between the average concentration and nominal concentration. Precision was estimated by total and intra-run coefficients of variation (CVs). Intra-run CVs were calculated as the pooled relative standard deviation (RSD) for all runs. The requirements were +15% for both accuracy and precision at all concentrations, except at the limit of quantification (LOQ), at which the requirement was +20%. Intermediate precision was monitored by analyzing QC samples. The LOQ was determined as the lowest concentration fulfilling the requirements for accuracy and precision.
Recovery was measured by spiking five different matrices (two from postmortem cases, two from living donors and one BB) that tested negative for the analytes. The matrices were prepared in triplicate and spiked at two concentrations (10 or 100 ng/g) before and after sample preparation. The recovery was then calculated by using the ratio between the peak areas of the samples spiked pre-extraction and the samples spiked postextraction. The matrix effect was determined by using the ratio of the peak area of samples spiked post-extraction and spiked mobile phase as explained by Matuszewski and coworkers (33) .
Carry-over in the sample preparation was determined by analyzing a blank matrix sample in a well adjacent to high concentration wells. Carry-over in the analytic procedure was determined by analyzing a blank sample consisting of mobile phase following a high-concentration matrix sample (500 ng/g). This procedure was repeated five times, and the areas of any peaks in the blank samples were compared to the area of a peak at the LOQ.
Stability of the diluted reference standard solutions of MPH in water was studied by storing three 0.1 mg/L samples at room temperature, 4, -20, and -808C and analyzing them in duplicate after one month. Because RA is inherently more stable than MPH, it was only stored at 48C and -208C and analyzed after three months. Comparisons were made to freshly prepared reference samples.
Bench-top and freeze-thaw stability in blood was investigated by preparing samples at two concentrations (10 and 100 ng/g). The bench-top stability samples were left at room temperature for six hours. The freeze-thaw stability samples were frozen for 24 h, followed by unassisted thawing at room temperature for 1 h. This freeze-thaw cycle was repeated twice. The samples were then prepared and analyzed in triplicate. Comparisons were made to reference samples prepared in the same run and stored at -808C.
The stability of extracts in sealed microtiter plates was examined by re-analyzing QC samples after storage at ambient temperature for 24 h. Long-term stability of the analytes in blood was determined by storing samples spiked at two concentrations (10 and 100 ng/g) in 1-mL Nunc cryotubes at -208C. The samples were then prepared and analyzed in triplicate after 17 days of storage.
Application to forensic cases
The method was applied to femoral blood samples from authentic forensic cases gathered in the time period 2010-2011. Twelve postmortem blood samples from autopsy cases and 10 antemortem blood samples from a mixture of traffic, violence and sexual assault cases were analyzed in duplicate. For the postmortem and antemortem violence/rape cases, the samples were taken in the forensic department, transferred to tubes containing 1% sodium fluoride and immediately stored at -208C. The antemortem traffic cases were sampled by a medical doctor associated with the police, transferred to tubes containing 1% sodium fluoride, and sent uncooled by mail to the forensic department.
Results and Discussion

Method development
Polymeric cationic mixed-mode SPE cartridges were first attempted in the sample preparation, but they resulted in low recovery of RA. Polymeric mixed-mode SPE cartridges provided good recovery of all four analytes, but the extracts were redcolored, likely from retained heme proteins that co-eluted from the cartridges with the analytes. To attain better clean up, a protein precipitation step was introduced before SPE to remove the proteins. This step provided reasonable recovery with clear extracts.
Chromatography (Figure 2 ) provided good separation of the enantiomers of both analytes within 10 min. The l-RA eluted late in the chromatogram and had the broadest shape. Any attempt to sharpen this peak resulted in a lack of enantioselectivity between the two MPH enantiomers. Thus, a compromise had to be made between a sharp peak for l-RA and separation of the two MPH enantiomers. Small peaks for the erythro-MPH enantiomers, which are found as impurities in threo-MPH, were observed (Figure 2) . The erythro enantiomers of RA eluted before the threo enantiomers [retention time (R t ) 2.5 min] and were unresolved.
Method validation
No interference was observed from the three analyzed substance mixtures. Injection of rac-threo-MPH resulted in small peaks for the threo-RA enantiomers ( peak area ,0.1% of threo-MPH peak area), likely a result of spontaneous hydrolysis of MPH to RA in solution. The same phenomenon was observed for the internal standards. No interference was observed between the analytes and their corresponding internal standards.
Ion suppression and, for RA, ion enhancement, was observed in the region between 1.5 and 3 min (Figure 3) , likely due to phospholipids because it corresponds to the interval where the majority of the phospholipids elute. No ion suppression was observed for MPH or its internal standard after 4 min. Ion suppression of up to -30% was observed for both RA and its IS in the area around 4 min for some of the blank matrices, which is in the retention time window for d-RA and could potentially be a problem, although the internal standard likely compensates for this effect, because the ion suppression profiles were close to identical (Figure 3) .
A linear calibration curve could not be achieved for any of the four analytes, but a second order model with a weighting factor of 1/x was applied and, using this model, an accuracy of 85-115% was achieved for all analytes in the range of 0.2 to Tandem Mass Spectrometry 563 500 ng/g for spiked samples. The LOQ was determined to be 0.5 ng/g for all analytes.
Precision and accuracy data are shown in Table II . At concentrations above the LOQ, intra-run and total CVs were less than 10% for MPH and less than 15% for RA. At the LOQ, intra-run and total CVs were less than 15% for MPH and less than 20% for RA. As the ion suppression experiments have shown, RA is generally more prone to ion suppression, which may be a reason for the somewhat higher CVs than those of the parent compound. In addition, l-RA is the latest eluting and broadest peak in the chromatogram (Figure 2) , which is likely to increase the CVs for this enantiomer. For all analytes, accuracy was within 85-115% at concentrations above the LOQ and within 80 -120% at the LOQ.
Extraction recovery was determined to be 32 -53% for MPH and 45 -59% for RA. The reason for the low recovery is the protein precipitation step, but it should not be a problem because deuterated internal standards were used with similar recoveries. The matrix effect was within +10% (minus indicates suppression and plus indicates enhancement) for the analytes, with few exceptions. For l-MPH, one postmortem matrix resulted in a matrix effect of -68 and -47% for the low and high concentration samples, respectively. For d-RA, one postmortem matrix resulted in a matrix effect of -43 and -54% for the low and high concentration, respectively. For d-RA, BB resulted in a matrix effect of -15%, which is consistent with the ion suppression observed for RA in some matrices at 4 min, as d-RA elutes in this region. Again, because similar matrix effects were observed for the internal standards, the internal standards should correct for the problem. No carry-over was observed in the sample preparation or analytic process.
The stability of 0.100 mg/L MPH in water was better than 95% after one month of storage at -20 or -808C. At 58C, 81 -90% of the substance remained, whereas only 7 -14% remained at ambient temperature. No degradation was observed for RA at 4 or -208C after three months of storage.
With two exceptions, freeze-thaw and bench-top stability in blood was within 90 -110% for all analytes. The bench-top stability of 100 ng/g d-RA and l-RA was 82 and 76%, respectively. Measured values for extracts in microtiter plates after storage in the autosampler for 24 h at ambient temperature were 92 to 109% of the initially measured values for all analytes. The longterm stability in blood, measured after 17 days of storage at -208C, was better than 95% (mean of triplicate measurements) for MPH at low (10 ng/g) and high (100 ng/g) concentrations, better than 80% for the low concentrations of RA, and better than 75% for the high concentrations of RA.
Forensic cases
The method was applied to a series of authentic forensic blood samples, both postmortem (Table III) and antemortem cases, including traffic and violence cases (Table IV) . The postmortem cases consisted of eight men and four women, aged 26 -49 years. Nine of the cases were drug addicts with supposed poisoning as the cause of death, and the rest of the causes of death were not related to drugs. MPH was not judged to have any significance with regard to death in any of the cases. Using the terminology of Druid and Holmgren, the cases can be regarded as C cases with regard to MPH, i.e., the observed drug ranges can be regarded as postmortem reference intervals for the supposed non-intoxicated state (34) . The d-MPH concentration ranged from 5 to 58 ng/g (median 15), whereas l-MPH ranged from undetected to 48 ng/g (median BLOQ). The sum ranged from 5 to 89 ng/g, corresponding to reported therapeutic concentrations in plasma or serum for living subjects; for example, Schulz and Schmoldt reported an interval of 10 -60 ng/mL (35) . Josefsson and Rydberg also reported a somewhat similar range (trace to 95 ng/mL) for 10 postmortem cases (24) . The d/l-ratio for MPH could be determined for four of the cases (0.9 -7.9). Thus, apart from case 8, d-MPH exhibited the highest concentration in the postmortem cases, a pattern similar to that of living subjects that reflects preferential metabolism of the l-form (8) . d-MPH constituted 86-100% of total MPH (median 100%), except in Case 8, where it constituted 46%. The concentration of RA was generally more than 10 times higher than that of the parent compound, with a more equal distribution of the d-and l-forms (median ratio 0.9), which corroborates the findings of Aoyama and coworkers (36) . Table IV presents the results for 10 living subjects. None of these subjects were judged to be intoxicated by MPH, so these values can be regarded as representative for living subjects in a non-intoxicated state. The results are generally of the same order of magnitude as for the postmortem cases, with a dominance of d-MPH compared to l-MPH, and a more equal distribution of the enantiomers of RA, which occur at concentrations approximately 10 or more times higher than the parent compound. The similarity of the concentration pattern with the postmortem measurements suggests that MPH is not subject to any significant postmortem redistribution. The order of magnitude of the concentrations corresponds to previously published chiral measurements of MPH for living subjects in serum or plasma (8, 10, 14, 21, 22, 25, 36 -39) . In the living, d-MPH constituted 50 -100% of total MPH (median 100%).
Thus, in most individuals there is a predominace of the d-form, but in a few cases the ratio is closer to 1. This may reflect genetic polymorphisms in the CES1 gene, although other factors, such as preferential hydrolysis of the d-form by plasma esterases in the samples in vitro, may also be involved.
Conclusions
A chiral method was developed for quantifying MPH and RA based on automated SPE and LC -MS-MS. This is the first reported chiral measurement of MPH and RA in whole blood. It proved suitable for measuring the enantiomers of MPH and RA in blood from forensic cases. Moreover, it may also prove valuable for applications in clinical pharmacology.
Application of this method revealed that concentrations of the analytes were of the same order of magnitude in postmortem blood and blood from living subjects not suspected of intoxication, with the active d-enantiomer of MPH predominating. This pattern agrees with previous chiral measurements in Table III Concentrations plasma or serum from living subjects. Thus, MPH is likely not subjected to any significant degree of postmortem redistribution. RA occurred in concentrations more than 10 times higher than those of the parent compound with an equal distribution of the enantiomers. These concentrations may serve as a reference for the interpretation of chiral measurements of MPH and RA in forensic cases. A major advantage of this method is that the sample preparation setup offers a fully automated process, with no human intervention necessary. Moreover, the simultaneous detection of the d-and l-forms of MPH and its primary metabolite RA offers possibilities for a more detailed evaluation of cases of intoxications with MPH. This includes detection of changes in the stereospecificity of the CES1-mediated metabolism of MPH possibly reflecting genetic variations.
